Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.74 |
| ▸ | KMO | O15229 | 1/20 | 0.53 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.49 |
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | DBH | P09172 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471547 | 0.98 | HDAC4 (0.72) | HDAC4HDAC2HDAC8KMOACMSD | |
| SCHEMBL21471491 | 0.85 | HDAC4 (1.00) | HDAC4HDAC2HDAC8KMOACMSD | |
| SCHEMBL23258680 | 0.84 | HDAC4 (0.54) | HDAC4HDAC2HDAC8KMOACMSD | |
| SCHEMBL23258566 | 0.84 | QDPR (0.62) | HDAC4HDAC2HDAC8KMOQDPR | |
| SCHEMBL21471492 | 0.84 | HDAC4 (0.96) | HDAC4HDAC2HDAC8KMOACMSD | |
| SCHEMBL23250752 | 0.83 | HDAC4 (0.53) | HDAC4HDAC2HDAC8KMOACMSD | |
| SCHEMBL23433185 | 0.82 | HDAC4 (0.53) | HDAC4HDAC2HDAC8KMOACMSD | |
| SCHEMBL23250721 | 0.80 | HDAC4 (0.49) | HDAC4HDAC2HDAC8KMOQDPR | |
| SCHEMBL778529 | 0.79 | HDAC4 (0.63) | HDAC4HDAC2HDAC8KMOACMSD | |
| SCHEMBL23250778 | 0.78 | HDAC4 (0.47) | HDAC4HDAC2HDAC8KMOQDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073131-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20210163393-A1 | HINOKITIOL ANALOGUES, METHODS OF PREPARING AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2021-06-03 | — | — | US | disclosed |
| WO-2019200314-A2 | HINOKITIOL ANALOGUES, METHODS OF PREPARING AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163393-A1 | HINOKITIOL ANALOGUES, METHODS OF PREPARING AND PHARMACEUTICAL COMPOSITIONS THEREOF | CYP27A1, CYP27B1, HSD17B7 | HDAC4 1472/4885HDAC2 766/4885HDAC8 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.